Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (16428)	11/14/2003 6:06:29 PM
From: Bluegreen	Read Replies (1) \| Respond to of 17367

George, have you seen the MASSIVE accumulation of Xoma stock by institutions??? UNBELIVEABLE!!!!! Stars of the show include PRIME CAP and FMR!!!!! WHY IN THE WORLD WOULD ANY OF THEM BUY XOMA????? Info. is at the Nasdaq site and even has updated total shares out on Xoma. Even with this updated total shares it shows well over 40% held by the big boys. Many new buyers and almost 100 count of the big guys. I agree, with you on the fact that most average joe investors have probably been completely crushed by Xoma. I think Bob is referring to 2006 IF everything hits on all cylinders. As you know you only have to wait a VERY SHORT period of time to see the uptake of Raptiva. Remember too, either Neuprex zaps zits or not......NOT anything like sepsis trial. Keep in mind they plan to develop and market it on their own for acne. People and the media will start asking ALOT of questions why they can't take it for other infections IF it works on acne. Maybe then someone will get to the bottom of why the SUBPART E designation guidelines were NOT followed in the approval process of the Meningo. trial.